Hyperlipoproteinemia and apheresis. Clinical experience with the H.E.L.P.-system;Hyperlipoproteinämie und LDL-apherese. Klinische erfahrungen mit dem H.E.L.P.-system

Herz

Volumn 26, Issue 8, 2001, Pages 531-544

  Jaeger, Beate Roxane ^a   Seidel, Dietrich ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Clinical experience with LDL apheresis; Coronary heart disease; Hyperlipoproteinemia; LDL apheresis; Therapy of lipid metabolism

Indexed keywords

ANTILIPEMIC AGENT; FIBRINOGEN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STATIN;

APHERESIS; ARTICLE; ATHEROSCLEROSIS; DIETARY INTAKE; HUMAN; HYPERLIPOPROTEINEMIA; ISCHEMIC HEART DISEASE; LIPID METABOLISM; MORTALITY; RISK FACTOR; TREATMENT PLANNING;

EID: 0035673667     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00002058     Document Type: Article

References (64)

1. Über den gehalt normaler und atheromatöser aorten an cholesterin und cholesterinestern
2. Preventing coronary artery disease by lowering cholesterol levels
3. Empfehlungen der Deutschen gesellschaft zur bekämpfung von fettstoffwechselstörungen und ihre folgeerkrankungen
4. Lipid lowering, regression,and coronary events: A review of the interdisciplinary council in lipids and cardiovascular risk intervention, seventh council meeting
5. A macro and micro view of coronary vascular insult in ischemic heart disease
6. On the pathogenesis of atherosclerosis: Enzymatic transformation of human low density lipoprotein to an atherogenic moiety
7. The lipid-rich core region of human atherosclerotic fibrous plaques
8. Modulation of coronary vasomotor tone in humans - Progressive endothelial dysfunction with different early stages of coronary atherosclerosis
9. The pathogenesis of coronary artery disease and the acute coronary syndromes (first of two parts)
10. The pathogenesis of coronary artery disease and the acute coronary syndromes (second of two parts)
11. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: Results from the prospective Göttingen Risk, Incidence and Prevalence Study (GRIPS)
12. Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS), I. Risk factors for myocardial infarction in a cohort of 5790 men
13. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
14. Prevalence of coronary heart disease in the Framingham Offspring Study: Role of lipoprotein cholesterol
15. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain
16. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina
17. A Six year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants
18. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
19. The sequence of cell and matrix changes in atherosclerotic lesions of coronary arteries in the first forty years of life
20. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the northwick park heart study
21. Relationship of fibrin deposition in microvasculature to outcomes in cardiac transplantation
22. Plasma fibrinogen - An independent cardiovascular risk factor
23. Plasma fibrinogen as a predictor of total and cause-specific mortality in elderly Japanese-American men
24. The HELP-LDL-apheresis multicenter study, an angiographically assessed trial into the role of LDL-apheresis in the secondary prevention of coronary heart disease: I. Evaluation of safety and cholesterol-lowering effects during the first 12 months
25. The H.E.L.P.-LDL-Apheresis Multicenter Study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease
26. Aggressive lowering of fibrinogen and cholesterol in the prevention of graft vessel disease after heart transplantation
27. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
28. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study
29. A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study
30. The H.E.L.P.-apheresis therapy in the treatment of severe hypercholesterolemia: 10 years of clinical experience
31. Evidence for maximal treatment of atherosclerosisdrastic reduction of cholesterol and fibrinogen restores vascular homeostasis
32. Consistent lowering of clotting factors for the treatment of acute cardiovascular syndromes - A different pathophysiologic approach
33. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
34. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
35. The effect of fluvastatin on coronary events in patients with symptomatic coronary artery disease during one year of treatment
36. Formes homozygotes cutanėo-tendineuses de xanthomatose hypercholésterolémique dans une observation familiale exemplaire. Essai de plasmaphèrèse à titre de traitement héroique
37. A new approach to the management of familial hypercholesterolemia: Removal of plasma cholesterol based on the principle of affinity chromatography
38. Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia
39. Selective continuous elimination of low density lipoproteins (LDL) by heparin precipitation: First clinical application
40. Removal of low-density lipoproteins (LDL) and fibrinogen by precipitation with heparin at low pH: Clinical application and experience
41. Low density lipoprotein plasmapheresis with and without lovastatin in the treatment of the homozygous form of familial hypercholesterolemia
42. The H.E.L.P.-LDL-Apheresis Multicenter Study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease
43. Early and drastic reduction of plasma fibrinogen and LDL-cholesterol by H.E.L.P.-apheresis for the prevention of graft vessel disease after cardiac transplantation
44. Selective removal of apolipoprotein B-containing serum lipoproteins from blood plasma
45. Behandlung einer Hypercholesterolämie durch extrakorporale Immunadsorption
46. DALI apheresis in hyperlipidemic patients: Biocompatibility, efficacy, and selectivity of direct adsorption of lipoproteins from whole blood
47. Diagnostik und therapie der dyslipoproteinämien
48. Prevention of premature coronary atherosclerosis in homozygous familial hypercholesterolemia by H.E.L.P.-apheresis a follow-up study over 13 years
49. What is the role of lipid lowering therapy in heart-allograft failure?
50. Lipid disorder and transplant coronary artery disease in long-term survivors of heart transplantation
51. Influence of single LDL apheresis on coronary vasodilatation capacity in suffering from coronary artery disease with increased lipoprotein(a) level and low LDL cholesterol
52. Improvement of coronary vasodilatation capacity after single LDL-cholesterol apheresis: Does the initial LDL-cholesterol level influence the therapeutic effect?
53. Coronary artery disease in children with familial hypercholesterolemia - Maximum therapy utilizing LDL apheresis
54. Der akute Einfluß der H.E.L.P.-Apherese auf den myokardialen Blutfluß und die koronare Flußreserve bei herztransplantierten Patienten
55. 2-reactivity after heparin-mediated extracorporeal LDL precipitation in patients with coronary heart disease and hypercholesterolemia
56. Heparin-induced extracorporeal LDL/Fibrinogen Precipitation - H.E.L.P. in coronary and cerebral ischemia
57. Improved hemorrheology associated with a reduction in plasma fibrinogen and LDL in patients being treated by heparin-induced extracorporeal LDL precipitation (HELP)
58. Safety and effectiveness of long-term LDL-apheresis in patients at high risk
59. Heparin-induced extracorporeal low-density lipoprotein precipitation (H.E.L.P.) to improve the recovery of hearing in patients with sudden idiopathic hearing loss